This message contains images. If you don't see images, click here to view. Click
here to advertise in this news brief.
|
|
|
|
Study: Association of HLA mismatch with death with a functioning graft after kidney transplantation
American Journal of Transplantation (subscription required)
Share
  
HLA mismatches may correlate with risk of death with a functioning graft (DWFG) because of requirement for higher immunosuppression doses and more antirejection therapy. Deceased-donor kidney transplants (n = 177 584) performed 1990–2009 and reported to the Collaborative Transplant Study were analyzed. Multivariable analysis showed that mismatches for HLA class II were more strongly associated with both hospitalization and DWFG than mismatches for HLA class I.
More
 |
• We are an FDA licensed manufacturer.
• We label peptides, monoclonal antibodies, reagents, chemical and proteins for cancer treatments.
• Our above products can be labeled with radioisotopes such as I-125, I-131, P32, Tc99m, Y90 and AC-225. • We have a multicurie isotope license and an animal facility.
|
PRESIDENT'S CORNER |
Roslyn Mannon, MD
 2012 Election results: What they mean for you
After what feels like an eternity of partisan campaigning among elected officials at all levels, the 2012 election cycle has finally ended. AST President, Dr. Roslyn Mannon's latest blog post discusses what the election results may mean to you. Read and comment on this blog.
|
Nov. 30 AST board nomination deadline
AST
Share
  
This is a reminder that the deadline for submission of AST board of director nominations is Nov. 30. Open positions for the 2013-2014 Board include a one-year president-elect term and three councilor-at-large positions (each for three-year terms). The term of service will begin at the annual members' business meeting scheduled for May 20, 2013 at the American Transplant Congress. For a nomination to be seriously considered, the nominee should have had significant involvement in, and service to, the AST. The nominee should have demonstrated ability to think strategically, commit to working effectively within a collective decision-making body and have knowledge of or experience with governance. Please visit the AST website to submit a nomination.
 |
Identify Antibodies That May Compromise Graft Survival
- Detect Presence of Complement Fixing Antibodies
- Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit! FREE SAMPLE
For Research Use Only. Not for use in diagnostic procedures.
|
Register now and save; learn about our expert speakers
AST
Share
  
Register by Nov. 30 for the Cutting Edge of Transplantation (CEOT) meeting in Scottsdale, Ariz., and take 50 percent off regular rates. The meeting takes place at the beautiful Sheraton Wild Horse Pass Feb. 14-16, 2013. Learn more about the program and the expert speakers here.
Transplant surgery lecture addresses over-prioritization of HCC patients
Healio
Share
  
Dr. Elizabeth A. Pomfret discussed the prioritization of patients with hepatocellular carcinoma for liver transplantation during a lecture at The Liver Meeting. Patients with HCC are often given priority for transplantation, Pomfret said, when surgical resection can serve as well or even better in some cases, such as for patients with normal remnant liver parenchyma, Child's A cirrhosis, no portal hypertension or varices, a single tumor, or HBV infection as opposed to HCV.
More
Living donor transplant chains help minorities
Renal & Urology News
Share
  
Nearly half of kidney recipients in living donor transplant chains are minorities, according to a new study by UCLA researchers. John Schieszer reports in today's Medical Minute that the findings may help allay fears that minorities would be disadvantaged by expansion of the donor pool.
More
Exception point applications for 15 points: An unintended consequence of the Share 15 policy
Liver Transplantation (subscription required)
Share
  
In 2005, the United Network for Organ Sharing adopted the Share 15 policy to improve organ allocation by facilitating transplantation for local and regional patients with Model for End-Stage Liver Disease (MELD) scores of 15 or higher. There has been concern that the lack of standardization in the use of exception points is potentially diminishing the benefits of this policy. Recent analyses demonstrate several important changes in practice that have occurred as a result of the implementation of the Share 15 policy.
More
Renal-sparing regimens employing new agents
Current Opinion in Organ Transplantation (subscription required)
Share
  
A persistent challenge facing the transplant community is avoiding renal compromise, whether protecting a newly placed kidney allograft or preserving native renal function after another organ has been implanted. One of the principal ways to achieve this is by altering the immunosuppressive regimen. As no drug regimen yet demonstrates an overwhelming benefit over calcineurin inhibitors, particularly regarding overall efficacy, efforts should continue to move forward toward the goal of minimizing chronic kidney disease.
More
|
|
|
|
 |
|
Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
|
|
|
|
 |
|
✓ Hypothermic preservation of a single kidney using physiologic pulsatile preservation and membrane oxygenation: a proven technology from Waters Medical Systems (more than 40 years clinical experience)
✓ Simplifies the perfusion process (provides more options to view, chart, and trend data, offers web-based remote monitoring, and a transportable design)
✓ Meets or exceeds current FDA standards and AOPO and UNOS Preservation Guidelines.
|
|
|
|
 |
|
When it comes to saving lives, MNX understands organ transplant logistics. Every shipment is urgent, and every step critical. That’s why MNX offers specialty services that are tailored for organ transportation. From expedited ground service to charter flights, MNX has the proven experience and operational resources you can count on.
|
|
Belatacept in kidney transplantation
Current Opinion in Organ Transplantation (subscription required)
Share
  
In June 2011 the US Food and Drug Administration approved belatacept for the prophylaxis of organ rejection in adult kidney transplant recipients. This review discusses the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen.
More
Changes in biomarkers of bone resorption over the first 6 months after pediatric hematopoietic cell transplantation
Pediatric Transplantation (subscription required)
Share
  
Bone loss has been observed within the first six months after HCT in both children and adults. While there is some evidence that bone formation may be reduced in children after HCT, it is currently unknown whether bone resorption is increased. The objective of this prospective study was to evaluate changes in markers of bone resorption over the first six months after pediatric HCT.
More
Evaluating the utility of ambulatory blood pressure monitoring in kidney transplant recipients
Clinical Transplantation (subscription required)
Share
  
Hypertension is a major risk factor for graft dysfunction and cardiovascular disease in kidney transplant recipients (KTX). Accurate monitoring is therefore essential to provide optimal therapy. Researchers evaluated whether 24-hour ambulatory blood pressure monitoring is superior to clinic blood pressure measurement in prevalent KTX.
More
Detection of alcohol consumption in patients with alcoholic liver cirrhosis during the evaluation process for liver transplantation
Liver Transplantation (subscription required)
Share
  
Alcoholic liver cirrhosis is a commonly accepted indication for liver transplantation (LT). Any alcohol consumption is considered a contraindication for LT. However, the assessment of abstinence in everyday practice mostly relies on patient self-reporting, which must be considered highly unreliable. After consumption, ethanol is eliminated by alcohol dehydrogenase, with methanol accumulating in the blood. Methanol, which is known to be a sensitive and specific indicator for recent alcohol consumption, has not been used for verifying alcohol consumption in LT assessments yet.
More
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|